Trellis Bioscience, Inc. is a venture backed biopharmaceutical company whose breakthrough technology for the discovery and optimization of peptide therapeutics enables a qualitatively new approach to inhibiting protein-protein interactions. Such interactions are central to most biological processes - from intracellular and extra cellular communication, to programmed cell death - and represent a large and important class of targets for human therapeutics. Despite the plethora of such targets that have been identified over the past decade, most drug discovery technologies have been unable to identify drug-like molecules that interfere with these interactions. Trellis has combined its proprietary multiplex detection technology with in-licensed technology from a prominent university laboratory, enabling the rapid generation of small, highly stable peptide scaffolds that potently and selectively block these important targets. Using this highly efficient platform the company will develop a pipeline of clinical candidates, with an initial focus in the discovery and development of cancer therapeutics.

Click Here to contact us about: Trellis Bioscience Inc..

InvestBio structures institutional quality investment opportunities for the qualified individual investor. Our scientific advisors have access to valuable industry insights, allowing us to identify the most promising research and drugs. We structure an investment partnership for our clients and typically invest side-by-side, at the same price and timing, in targeted private equity investments. This approach allows our interests to be directly aligned with our investors. On Wall Street, these investment opportunities are often only accessible to institutional investors, however, we at InvestBio believe that these opportunities should also be available to the qualified individual investor. We make that happen. InvestBio is a wholly owned subsidiary of DPEC Partners.